BIIB peer analysis
Biogen (BIIB) against its competitors: price, today's move, 1-year return and market value side by side.
BIIB and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ALNY Alnylam | $157.89 | -4.31% | -64.88% | $22.10B |
| AMGN Amgen | $467.48 | 0.32% | 60.10% | $251.94B |
| AZN AstraZeneca | $186.61 | -0.02% | 13.32% | $289.48B |
| IONS Ionis Pharmaceuticals | $41.21 | -5.31% | -44.44% | $7.23B |
| LLY Eli Lilly | $1,413.00 | -0.32% | 67.32% | $1.26T |
| PFE Pfizer | $31.04 | 1.70% | 27.79% | $173.95B |
| PTCT PTC Therapeutics | $60.84 | 1.45% | -10.67% | $5.01B |
| REGN Regeneron | $961.34 | 3.60% | 46.98% | $95.99B |
| UTHR United Therapeutics | $596.83 | -0.32% | 31.60% | $25.68B |
| VRTX Vertex | $564.99 | 1.09% | 34.56% | $141.65B |
| BIIB Biogen | $248.96 | -1.84% | 66.41% | $37.49B |
- BIIB's peers: ALNY (Alnylam), AMGN (Amgen), AZN (AstraZeneca), IONS (Ionis Pharmaceuticals), LLY (Eli Lilly), PFE (Pfizer), PTCT (PTC Therapeutics), REGN (Regeneron).
Updated 2026-11-02 23:13 UTC